Posted by Michael Wonder on 26 Oct 2022
CorVista Health receives breakthrough device designation for the CorVista system
25 October 2022 - CorVista Health announces that the US FDA has granted breakthrough device designation for the CorVista System as a first non-invasive point of care diagnostic solution for patients with suspected pulmonary hypertension.
The CorVista System offers two important improvements to the current standard of care for diagnosing pulmonary hypertension – expansion of the population for use of a non-invasive, point of care test and potential for significant reduction in time to diagnosis and treatments thereby allowing improved patient outcomes.
